Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MBDA Score, RA Disease Activity Measures Linked

Arthritis Care Res; ePub 2018 Oct 15; Johnson, et al

The multi‐biomarker disease activity (MBDA) score demonstrates moderate convergent validity with Disease Activity Score 28-joint count C-reactive protein (DAS28‐CRP) and DAS erythrocyte sedimentation rate (DAS28‐ESR), but weaker correlations with Simple Disease Activity Index (SDAI), Crohn's Disease Activity Index (CDAI), and Routine Assessment of Patient Index Data 3 (RAPID3). This according to a systematic review of the MBDA and meta‐analysis of the correlation between the MBDA and other rheumatoid arthritis (RA) disease activity measures. The review searched literature from inception to March 7, 2017. Correlations of the MBDA with composite RA disease activity measures were pooled using random‐effects meta‐analyses. Researchers found:

  • 22 studies were identified, of which 8 (n=3,242 assays) reported correlations of the MBDA with RA disease activity measures.
  • Pooling results from these 8 studies in the meta‐analysis, the MBDA demonstrated modest correlations with DAS28‐CRP (r = 0.41) and DAS28‐ESR (r = 0.48) with weaker correlations observed with SDAI (r = 0.35), CDAI (r = 0.26), and RAPID3 (r = 0.23).


Johnson TM, Register KA, Schmidt CM, et al. Correlation of the multi‐biomarker disease activity score with rheumatoid arthritis disease activity measures: A systematic review and meta‐analysis, [Published online ahead of print October 15, 2018]. Arthritis Care Res. doi:10.1002/acr.23785.